Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Constraints

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    67 result(s) found for: Constraints. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2014-002590-10 Sponsor Protocol Number: P130906 Start Date*: 2016-02-11
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Effect of bronchodilators on effort induced dyspnoea in patients suffering lung hypertension
    Medical condition: Idiopathic or heritable patients with pulmonary arterial hypertension (PAH).
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004766-17 Sponsor Protocol Number: zoledronate-fract-65-85yr Start Date*: 2021-06-30
    Sponsor Name:Region Uppsala
    Full Title: The Fragility Fracture Trial (FFT): A randomized, double-blind, placebo-controlled trial to investigate whether zoledronic acid prevents new fractures in older adults with a recent non-hip, non-ver...
    Medical condition: Non-hip, non-vertebral fragility fracture
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004047-23 Sponsor Protocol Number: 273551-2 Start Date*: 2019-12-05
    Sponsor Name:University of Bergen
    Full Title: Evaluation of safety and feasibility of autologous MSCs combined to biomaterial to enhance bone healing in patients with delayed consolidation after long bone defects requiring graft apposition or ...
    Medical condition: Diaphyseal and/or metaphysodiaphyseal fractures (femur, tibia, humerus) status delayed union (after 3 months) treated by standard care procedures
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-007497-37 Sponsor Protocol Number: GINECO-OV214 Start Date*: 2009-01-28
    Sponsor Name:ARCAGY
    Full Title: ESSAI EN DEUX ETAPES DE L’EVALUATION DE LA LENALIDOMIDE (REVLIMID®) DANS LE CANCER DE L’OVAIRE EN RECHUTE TARDIVE (> 6 MOIS): - EN MONOTHERAPIE CHEZ DES PATIENTES ASYMPTOMATIQUES AVEC UNE ELEVATIO...
    Medical condition: Ovarian cancer patients in late relapse
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005441-13 Sponsor Protocol Number: C11-12 Start Date*: 2013-01-03
    Sponsor Name:INSERM
    Full Title: Evaluation of efficacy and safety of autologous MSCs combined to biomaterials to enhance bone healing in patients with delayed consolidation after long bone fracture requiring graft apposition or ...
    Medical condition: Closed or open Gustilo I ans II humerus, tibial or femur diaphyseal or metaphysodiaphyseal fracture.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10017081 Fracture delayed union PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022912-37 Sponsor Protocol Number: MP‐1501‐01 Start Date*: 2012-03-07
    Sponsor Name:Medicis Pharmaceutical Corporation [...]
    1. Medicis Pharmaceutical Corporation
    2. Dow Pharmaceutical Sciences
    Full Title: Multi-centre, open-label, long-term safety trial to assess the long-term safety of tretinoin clindamycin phosphate gel in patients from 12 to less than 18 years of age with acne vulgaris.
    Medical condition: Treatment of Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000497 Acnes HLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-001688-31 Sponsor Protocol Number: 604296B Start Date*: 2007-06-04
    Sponsor Name:Larime company of the Mediscis group
    Full Title: Monitoring des états cognitifs chez des sujets volontaires sains, sur 2 périodes, l'une avant et après administration d'une dose unique de Zolpidem, l'autre sans administration de traitement
    Medical condition: It's a phase II study performed on healthy volonteers. Zolpidem (DCI) will be administered to the volunteers in order to inducing a drowsiness and a hypoattentiveness. Zolpidem is indicated in the ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022437 Insomnia LLT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022918-15 Sponsor Protocol Number: 7001‐G2HP‐07‐02 Start Date*: 2012-03-07
    Sponsor Name:Dow Pharmaceutical Sciences
    Full Title: Multi-centre, randomized, double-blind, active- and vehicle-controlled trial to compare the efficacy and safety of tretinoin clindamycin phosphate gel to clindamycin phosphate gel alone, tretinoin ...
    Medical condition: Treatment of acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000497 Acnes HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-022919-20 Sponsor Protocol Number: MP-1501-02 Start Date*: 2012-03-07
    Sponsor Name:Dow Pharmaceutical Sciences [...]
    1. Dow Pharmaceutical Sciences
    2. Medicis Pharmaceutical Corporation
    Full Title: Multi-centre, randomized, double-blind trial to compare the efficacy and safety of tretinoin clindamycin phosphate gel to clindamycin phosphate gel alone in the treatment of acne vulgaris in patien...
    Medical condition: Treatment of Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000497 Acnes HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-002283-41 Sponsor Protocol Number: 151032-002 Start Date*: 2017-09-11
    Sponsor Name:HRA Pharma
    Full Title: A prospective, randomized, parallel-group study to assess the effects on ovarian activity of ellaOne (ulipristal acetate 30 mg single dose) taken after three consecutive days of missed combined ora...
    Medical condition: Emergency contraception
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022911-20 Sponsor Protocol Number: 7001‐G2HP‐06‐02 Start Date*: 2012-03-07
    Sponsor Name:Dow Pharmaceutical Sciences
    Full Title: A Multi-Center, Phase 3, Randomized, Double-Blind, 4-Arm Clinical Trial to Compare the Safety and Efficacy of Clin-RA Gel vs. Clindamycin Phosphate 1.2% Gel vs. Tretinoin 0.025% Gel vs. Clin-RA Gel...
    Medical condition: Treatment of acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000497 Acnes HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000978-38 Sponsor Protocol Number: DSIT-2015-01 Start Date*: 2016-07-06
    Sponsor Name:DAIICHI SANKYO ITALIA S.P.A.
    Full Title: Randomized, prospective double-blind placebo controlled study for the evaluation of the number, duration and severity of Respiratory Tract Infections in adults with risk of recurrence after standar...
    Medical condition: Evaluation of clinical efficacy of Paspat 3 mg tablets in the prevention of number, duration and severity of Respiratory Tract Infections in adults with risk, defined as affected of at least 6 epis...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10038133 Recurrent respiratory tract infections LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004515-26 Sponsor Protocol Number: AGO-OVAR 15 Start Date*: 2006-01-06
    Sponsor Name:GYN Research GmbH
    Full Title: An open-label, multicenter, randomized phase II study to compare the effects of Paclitaxel/Carboplatin and Lonafarnib to those of Paclitaxel/Carboplatin for 1st line treatment of patients with epit...
    Medical condition: Female patients with cancer of the ovary, or cancer of the fallopian tube(s), or primary peritoneal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004577-30 Sponsor Protocol Number: EARLY-GENE Start Date*: 2022-03-11
    Sponsor Name:FUNDACION INVESTIGACION BIOMEDICA HOSPITAL PUERTA DE HIERRO MAJADAHONDA
    Full Title: EARLY treatment with Candesartan vs Placebo in asymptomatic GENEtic carriers of Dilated Cardiomyopathy (EARLY-GENE trial)
    Medical condition: Dilated Cardiomyopathy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024428-10 Sponsor Protocol Number: 10-PP-19 Start Date*: Information not available in EudraCT
    Sponsor Name:CHU de NICE
    Full Title: Traitement des épidermolyses bulleuses simples de type Dowling Maera par l'érythromicine orale
    Medical condition: Dowling Maera's bullous epidermolysis is a génodermatose with autosomique dominant transmission owed to transfers of the genes coding for keratins. It results from it a cutaneous fragility very sev...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10056508 Acquired epidermolysis bullosa LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2022-000168-22 Sponsor Protocol Number: SIK-FR-22-1 Start Date*: Information not available in EudraCT
    Sponsor Name:Addmedica
    Full Title: An open-label, non-comparative, multicentre study to evaluate the acceptability of a new paediatric formulation of hydroxycarbamide in children with sickle cell disease
    Medical condition: Drepanocytosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004850 10051835 Drepanocytosis LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001443-52 Sponsor Protocol Number: LLB-2019-02 Start Date*: 2019-11-13
    Sponsor Name:LABO'LIFE Belgium sprl
    Full Title: Randomized study to evaluate 2LVERU® JUNIOR and 2LVERU® efficacy on the treatment of warts. Protocol EVAsION
    Medical condition: Non genital warts infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10035150 Planar warts LLT
    20.0 100000004864 10035158 Plantar warts LLT
    20.0 100000004864 10047828 Warts LLT
    21.1 100000004864 10010115 Common warts LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001085-15 Sponsor Protocol Number: LLB-2018-01 Start Date*: 2019-11-06
    Sponsor Name:LABO’LIFE Belgium sprl
    Full Title: Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LHERP® in patients with recurrent orofacial herpes infections.
    Medical condition: Patients presenting recurrent orofacial herpes infections (6 or more episodes within the 12-months’ period prior to their study entry).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019972 Herpes viral infections HLT
    20.1 10021881 - Infections and infestations 10067152 Oral herpes PT
    21.1 10021881 - Infections and infestations 10019948 Herpes simplex PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003779-32 Sponsor Protocol Number: NL77171.091.21 Start Date*: 2021-09-27
    Sponsor Name:Radboud University Medical Center
    Full Title: HYPo-fractionated Radiotherapy of Lymph Node Metastases guided by NanO-MRI in Prostate Cancer Patients: A Pilot Study (HYPNO-study).
    Medical condition: men with biochemical recurrent prostate cancer after radical prostatectomy with ≤ 4 foci harbouring regional lymph node metastases (up to 6 lymph nodes in total) on nano-MRI.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000979-24 Sponsor Protocol Number: DSIT-2015-02 Start Date*: 2016-07-06
    Sponsor Name:Daiichi Sankyo Italia SpA
    Full Title: Randomized, prospective double-blind placebo controlled study for the evaluation of the number, duration and severity of Upper Respiratory Tract Infections in children with risk of recurrence after...
    Medical condition: upper respiratory tract infections in children at high risk of reccurence.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 01:38:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA